• Do Patients Continue Behavioral, Relaxation, and Dietary Strategies for IBS?

Do Patients Continue Behavioral, Relaxation, and Dietary Strategies for IBS?

A combination of cognitive behavioral therapy, relaxation, and dietary strategies reduced symptoms and increased quality of life in patients with irritable bowel syndrome (IBS), compared with usual care, researchers report in the February issue of Clinical Gastroenterology and Hepatology. The program produced sustainable behavioral changes in almost all participants after

Read more
  • Is Combination Therapy Most Effective for HBV Infection?

Is Combination Therapy Most Effective for HBV Infection?

A significantly greater proportion of patients receiving a combination of tenofovir disoproxil fumarate (TDF) and pegylated interferon-α (peginterferon) for 48 weeks lost hepatitis B surface antigen (HBsAg), a marker of hepatitis B virus (HBV) DNA transcriptional activity, compared to patients given the standard care (peginterferon or TDF alone), researchers report

Read more

Should Patients with Crohn’s Disease Continue Receiving Immunomodulators When Starting Anti-TNF Therapy?

Continued use of immunomodulator therapy in patients with Crohn’s disease receiving anti-tumor necrosis factor (TNF) therapy is no more effective than anti-TNF monotherapy in inducing or maintaining response or remission, researchers show. The meta-analysis of randomized controlled trials is published in the December issue of Clinical Gastroenterology and Hepatology. There is debate

Read more
  • Can Curcumin Treat Mild-to-Moderate Ulcerative Colitis?

Can Curcumin Treat Mild-to-Moderate Ulcerative Colitis?

Addition of curcumin to mesalamine therapy increases its ability to induce clinical and endoscopic remission in patients with mild-to-moderate active ulcerative colitis (UC), researchers show in the August issue of Clinical Gastroenterology and Hepatology. Patients with mild-to-moderate UC are usually treated with oral and/or topical mesalamine. Those who do not

Read more
  • Does Weight Loss Resolve Fatty Liver Disease?

Does Weight Loss Resolve Fatty Liver Disease?

Two separate studies in the August issue of Gastroenterology show that weight loss, via diet or bariatric surgery, reduce features of non-alcoholic steatohepatitis (NASH). Eduardo Vilar-Gomez et al associated extent of weight loss, produced by lifestyle changes, with level of improvement in histologic features of NASH. The highest rates of NASH reduction

Read more
  • Is FMT Ready for IBD?

Is FMT Ready for IBD?

Despite promising findings from 2 studies of fecal microbiota transplantation (FMT) in patients with ulcerative colitis, the technology should remain in clinical trials and is not ready for routine practice in patients with inflammatory bowel diseases (IBD), write Ari M. Grinspan and Colleen R. Kelly in an editorial. The success of FMT

Read more
  • Can we Promote Liver Regeneration in Patients with Decompensated Cirrhosis?

Can we Promote Liver Regeneration in Patients with Decompensated Cirrhosis?

The combination of granulocyte colony-stimulating factor (G-CSF) and a long-acting form of erythropoietin increases survival of patients with decompensated cirrhosis, researchers report in the June issue of Gastroenterology. The growth factor combination also improved liver function and reduced risk for septic shock within 1 y of treatment. Decompensation in patients

Read more
  • New Approaches to IBS and IBD, But Concerns About PPIs, Highlighted at DDW

New Approaches to IBS and IBD, But Concerns About PPIs, Highlighted at DDW

A new test to identify diarrhea-predominant irritable bowel syndrome (D-IBS) and a new class of drugs to treat ulcerative colitis were presented at Digestive Disease Week (DDW) in Washington DC, May 15–19. Researchers also warned that many residents of nursing homes are being inappropriately given proton pump inhibitors (PPIs). Mark Pimentel

Read more
  • Is Fecal Calprotectin a Good Marker of Crohn’s Disease Recurrence?

Is Fecal Calprotectin a Good Marker of Crohn’s Disease Recurrence?

The fecal concentration of calprotectin can be used to monitor for recurrence of Crohn’s disease, with a high enough negative predictive value that physicians can be confident they won’t miss patients with recurrent disease, researchers report in the May issue of Gastroenterology. Approximately 80% of patients with Crohn’s disease require surgery

Read more
  • Video: Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

Video: Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

Obeticholic acid significantly reduces biochemical features of primary biliary cirrhosis (PBC) in patients with an inadequate response to ursodeoxycholic acid (UDCA) therapy, Gideon M. Hirschfield et al report in the April issue of Gastroenterology. Hirschfield discusses the details of the study and its findings in a video abstract: PBC is a progressive, autoimmune

Read more